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Figure S1.  Confirmation of NOTCH3 mutations in the CADASIL iPSC lines. Related to Figure 1 and 2. A. DNA 
sequencing of genomic DNA extracted from 3 different clones (C3, C5 and C11) of Patient #1 iPSCs (AGD-14-01) 
demonstrating R153C mutation exists in all the 3 iPSC clones used in the study. B. Similarly, DNA sequencing of 
genomic DNA extracted from 3 different clones (C6, C10 and C16) of Patient #2 iPSCs (AGD-14-04) demonstrating 
C224Y mutation exists in all the 3 iPSC clones used in the study. C and D, representative DNA sequencing results 
demonstrating both R153C and C224Y mutations were absent in the control iPSCs (Control #1 AGD-14-02_C3 and 
Control #2 AGD-14-03_C7). 
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Figure S2. Establishment and characterisation of induced pluripotent stem cells (iPSCs). Ralated to Figures 1 
and 2. Figures show representative data on samples from CADASIL patient 1 (AGD-14-01). A. Schematic illustrates 
Sendai virus mediated delivery of OCT4, SOX2, KLF4 and C-MYC into dermal fibroblasts, and morphological changes 
of the dermal fibroblasts to form iPSCs after 28 days of the Sendai virus infection. B. Phase microscopy (top row) and 
imunofluorescence staining showing the three putative iPSC clones (AGD-14-01-C3, C5 and C11) chosen for 
subsequent experiments. All clones expressed pluripotency markers (Oct4, Sox2 and NANOG) with DAPI counterstain 
to show nuclei. C. Representative data from iPSC clone AGD-14-01-C3 shows a normal karyotype after 
reprogramming. D. PCR shows Sendai virus was undetectable in iPSCs after 10 passages. E. The iPSCs were able to 
form embryoid bodies (EB), and the EB outgrowths expressed markers of all three germ layers, the mesoderm 
(Brachyury), Neurectoderm (Nestin) and endoderm (GATA4) stained by immunofluorescence . Scale bars, 100 µm. 
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Figure S3. A-C. RT-qPCR determination of NOTCH-related gene expressions in the iPSC-MCs. Related to 
Figures 1 and 2. Gene expressions of NOTCH3 (A.) and Notch ligand JAG1 (B.) during the course of iPSC-MC 
differentiation. Data are presented as mean ± SEM of 6 clones, n = 6. C. Expression of Notch receptor subtypes 
(NOTCH 1-4) and target genes (HES1, HES2 & HEYL) in the differentiated iPSC-MCs from 3 CADASIL and 3 control 
clones. Data are presented as mean ± SEM, n = 3 indipendnat experiments. Two-way ANOVA and Turkey’s post-hoc 
test showed no statistical differences between data from the CADASIL and controls. D & E. Additional marker gene 
expression in iPSC derived MCs. D. RT-qPCR determination of the expression of SMC marker, SMMHC, in the iPSCs 
and iPSC-derived MCs (iPSC-MCs). Related to Figure 2. Data are mean ± SEM of representative samples from 3 iPSC 
clones from 3 independnent experiments (n=3). E. RT-qPCR determination of the expression of SMC marker, SMTH, 
during MC differentiation.  Data are mean ± SEM of a representative iPSC clone with 3 replications. 
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Figure S4. Primary SMCs isolated from the CADASIL patient failed to support angiogenic capillary structure in 
vitro. Related to Figures 3. SMCs isolated from small arteries of a CADASIL patient were co-cultured with HUVECs 
(HUV) in Geltrex on cover-glasses for in vitro angiogenesis assay. Human coronary artery SMCs (hCASMCs) were 
used as control. A. The capillary network was quantified and presented as mean total network length ± SEM, n=3. 
Statistical significance was determined by two-way ANOVA and Tukey’s post-hoc test. **p<0.01. B. The network 
structures were also double stained for α-SMA (red) and VE-cadherin (green), and counterstained by DAPI (blue). 
Scale bars, 200 μm  
 
A. 
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Figure S5. In Vivo angiogenesis analysis of iPSC derived endothelial cells and mural cells.  Related to Figures 3. 
A mixture of the CADASIL or control iPSC-MCs and iPSC-ECs in Matrigel were injected subcutanoursly into SCID 
mice. Two weeks after the Matrigel plugs were harvested and cryo-sectioned for immunostaining. Sections were stained 
using human specific anti-mitochondrial antibody (red), antibody against smooth muscle cell marker calponin (green), 
and counterstained with DAPI (blue). A. Arrows indicated capsules formed by host cells surrounding Matrigel plug. 
The majority of cells within the Matrigel plugs were positive for the antihuman antibody and of human origin, i.e., 
either  iPSC-MCs or iPSC-ECs. B. Images in the right column (e-h) are the magnified regions highlighted by a square 
in their corresponding figures on the left (a-d). Human iPSC-MCs (mitochondria+/calponin+ cells) were abundant in the 
control plugs (arrow heads in g and h), but the mitochondria+/calponin+ cells had almost disappeared within the patient 
plugs. The host MCs (human mitochondria-/calponin+) were located mainly in the capsules of the plugs (white arrows in 
A). Scale bars, 100 μm. 
A. 
 
B. 
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Figure S6. IPSC-MCs possess pericyte features and the role of PDGF-BB in angiogenesis. Related to Figures 3. 
A. eGFP labelled iPSC-MCs wrapping around unlabelled endothelial tubular structures in an in vitro Matrigel 
angiogenesis assay, indicative of pericyte function. Scale bar, 50μm. B. Immunocytochemistry staining showing that 
iPSC-MCs express a set of common markers of vascular pericytes. Scale bars, 200μm. C. Expression of angiogenesis-
associated genes in CADASIL and control iPSC-MCs determined by RT-qPCR. Data are mean ± SEM from 3 clones of 
a patient line and 3 clones of a control line, respectively, with triplicate assays for each sample, n = 3. Result showed 
downregulation of PDGFRβ in CADASIL iPSC-MCs as compared to the control. D. Western blotting of PDGFRβ in 
CADASIL and control iPSC-MCs (i.), and quantification of the band density (ii.) confirmed the reduced PDGFRβ 
protein level in CADASIL iPSC-MCs. Vimentin was used as sample loading control. Data are mean ± SEM, n = 3. 
Student t-test, ***p<0.001. E-G, In vitro tubule formation by CADASIL and control iPSC-ECs in the presence of 
exogenous PDGF-BB (E) or PDGFRβ inhibitor (F). G. Effect of exogenous PDGF-BB on the angiogenic tubule 
stability (solid lines) formed by co-culture of CADASIL (dotted red line) and control (dotted blue line) iPSC-ECs and 
iPSC-MCs. Data are mean ± SEM from 3 independent experiments using 3 iPSC clones from one patient and 3 iPSC 
clones from one control iPSC line, n = 3.  Two-way ANOVA with Tukey’s post-hoc test, ***p≤0.001, vs controls.  
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Figure S7. Quantification of the Proteome Profiler Human Angiogenesis Array and VEGF expression and effect 
on angiogenesis. Related to Figures 6 and 7.  A. The Proteome Profiler Human Angiogenesis Array Kit (ARY007, 
R&D systems) was used to screen angiogenesis related proteins secreted from the control and CADASIL iPSC-MCs in 
the conditioned media according to the manufacturer’s protocol. The density of the dots on the array films were 
quantified using ImageJ software. Data presented for each factor were the average of two separate blots using pooled 
culture media for the control and CADASIL iPSC-MCs, respectively. B & C. The expression of VEGF mRNA in 
primary VSMCs. RT-qPCR was performed on VSMCs obtained from CADASIL and control individuals in two 
separate studies (B and C).  B. Studies performed in cells from 3 patients and 5 controls showed a significant decrease 
in VEGF expression (*p<0.05). C. In a second set of experiments (n = 4/group), VEGF expression was reduced, but did 
not reach significance (p = 0.121) due to the heterogeneity in the control group. Data are mean ± SEM. Based on these 
differential results, we can conclude that there is a trend of decreased VEGF expression in the primary VSMCs in 
CADASIL.  D & E. Effects of VEGF on iPSC-EC capillary tubule formation. In vitro Matrigel assisted angiogenic 
tubule formation were carried out using CADASIL or control iPSC-ECs in the presence of recombinant VEGF-165 (D.) 
or VEGF receptor inhibitor (E.). Data are presented as mean ± SEM of 6 clones, n = 6. Statistical significance was 
determined by two-way ANOVA and Turkey’s post-hoc test, *p≤0.05, vs control.  
 
B.  
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Table S1. Primers used in RT-qPCR, related to Experimental Procesures. 
Gene  Forward (5’-3’) Reverse (5’-3’) 
OCT4/ POU5F1 AGACCATCTGCCGCTTTGAG GCAAGGGCCGCAGCTT 
NANOG TTAATAACCTTGGCTGCCGT GCAGCAAATACGAGACCTCT 
SOX-2 GGAGCTTTGCAGGAAGTTTG GCAAGAAGCCTCTCCTTGAA 
SOX-1 CCTCCGTCCATCCTCTG AAAGCATCAAACAACCTCAAG 
CNN1 GTCCACCCTCCTGGCTTT AAACTTGTTGGTGCCCATCT 
a-SMA ACTGCCTTGGTGTGTGACAA TCCCAGTTGGTGATGATGCC 
SM22a CGCGAAGTGCAGTCCAAAAT CAGCTTGCTCAGAATCACGC 
SMMHC GACTTCCCTGCTCAATGCCT GGACCTCTTCTCGTGGTTGG 
SMTN CGAAGCGCTGGTGAGTATGA CTCTGGCACCTCACACTGTT 
PDGFRβ ACCTGCAATGTGACGGAGAG GGGTGCGGTTGTCTTTGAAC 
ANG1  GAACACGATGGCAACTGTCG GCTGTATCTGGGCCATCTCC 
ANG2  CTAAGGACCCCACTGTTGCT CCATCCTCACGTCGCTGAATA 
VEGF-165 CTACGTCCACCATGCCAAGT GCACTAGCTGCGCTGATAGA 
KDR TGATGCCAGCAAATGGGAAT GCACCACGGCCAAGAGGCTTA 
ISL-1 AGATTATATCAGGTTGTACGGGATCA ACACAGCGGAAACACTCGAT 
Brachyury (T) GGGTCCACAGCGCATGAT TGATAAGCAGTCACCGCTATGAA 
PECAM1 (CD31) ATTTTGCACCGTCCAGTCC GAGTCCTGCTGACCCTTCTG 
VE-CADHERIN  ATCAAGCCCATGAAGCCTCT GGTCCTGCGGATGGAGTATC 
MESP1 AAGAAGAGCATGGGAGAGGTG CAGTTCCCCACCAGGTTCAAA 
PDGFRα GCGCAGGGAGTTTGAGAGAA CCACGGCCTCCAATGATCTC 
TEK (Tie2) TCCATGGAGAAACAGAGGCTGA TAGACCTCTTGGAGGAGGGAG 
KRIT1 (CCM1) AGCGCCTGTGAAGGAGATTC AGAACATGCGCTGAAGGTGA 
MMP9 TTTGAGTCCGGTGGACGATG GCTCCTCAAAGACCGAGTCC 
NOTCH3 CATCTCCGACCTGATCTGCC GTCTGTAGAGCGGTTTCGGA 
NOTCH1 AAGAATGGTGCCAAGTGCCT GAAGCAGAGGTAGGCGTTGT 
NOTCH2 GGAGGGACCTGCTCTGACTA TACCCAGGCCATCAACACAC 
NOTCH4 ATGTGTGTGTGACGTGGGTT GACATGGCCCTGAGTGACAA 
HES1 GAAAGATAGCTCGCGGCATT TGATCTGGGTCATGCAGTTGG 
HEY1 TCTGAGCTGAGAAGGCTGGT GATAACGCGCAACTTCTGCC 
JAG1 (JAGGED1) GCCTGTCAGTGATGTGCAAG TTCATTTGTTCTGCCTGTGC 
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Table S2. Antibodies used in immunoflorescence staining and western blotting, related to Experimental 
procesures. 
Antigen Antibody name Supplier Working 
concentration 
OCT4 Human/Mouse Oct-3/4 Antibody ( AF-
1759-SP) 
R&D Systems 1 µg/ml 
SOX2 Human/Mouse SOX2 Antibody 
(MAB2018-SP)  
R&D Systems 1 µg/ml 
SOX1 Anti-SOX1 antibody (ab22572) Abcam 2 µg/ml 
Brachyury (T) Human/Mouse Brachyury Antibody 
(2085-SP) 
R&D Systems 1 µg/ml 
Nestin Anti-Nestin antibody [10C2] (ab22035) Abcam 500 ng/ml 
GATA4 Human GATA-4 Antibody (AF2606-SP)  R&D Systems 2 ug/ml 
PECAM1 Human CD31/PECAM-1 Antibody 
(BBA7) 
R&D Systems 500 ng/ml 
VE-Cadherin Human VE-Cadherin Antibody 
(MAB9381-SP) 
R&D Systems 500 ng/ml 
VE-Cadherin 
conjugated 
(FACS) 
Human VE-Cadherin PE-conjugated 
Antibody 
(FAB93811P-025) 
R&D Systems 1 µg/ml 
Calponin Anti-Calponin antibody [EP798Y] 
(ab46794) 
Abcam 1 µg/ml 
SM22α Anti-SM22 alpha antibody (ab14106) Abcam 1 µg/ml 
αSMA Anti-alpha smooth muscle Actin antibody 
[1A4] (ab7817) 
Abcam 1 µg/ml 
NG2 Anti-NG2 antibody [132.38] (ab50009) Abcam 1 µg/ml 
PDGFRβ Anti-PDGF Receptor beta antibody [Y92] 
(ab32570) 
Abcam 500 ng/ml 
Vimentin Vimentin (V9) anti-Mouse (SC-6260) Santa Cruz 
Biotechnology 
500 ng/ml 
Human 
mitochondria  
Anti-Mitochondria (MAB1273) EMD Millipore 20 µg/ml 
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Supplimental Experiental Procedures 
 
Establishment of patient-derived iPSCs 
Punch skin biopsies were taken from two CADASIL patients carrying NOTCH3 mutations Arg153Cys (73 years 
old) and Cys224Tyr (58 years old), respectively, and a non-affected control individual (62 years old). The 
procedure for patient recruitment and iPSC generation was approved by the North West – Greater Manchester 
East branch of the National Research Ethics Service (REC reference NO 12/NW/0533). Both patients clinically 
presented with recurrent strokes and cognitive decline. Adult human dermal fibroblasts (HDFs) were purchased 
from Invitrogen as an additional non-CADASIL control. A 2-4 mm full-thickness skin plug was added to 0.25% 
Trypsin (Invitrogen) made up in sterile water and incubated for 10 minutes at 38oC. The sample was centrifuged 
at 500xg for 10 mins and the pellet was then treated with 0.5 mg/ml of collagenase at 38oC for 1 hour and 
centrifuged at 500g for 10 minutes and the supernatant discarded. The digested cell pellet was re-suspended in 
Chang D culture medium (Irvinesci) in a T25 cm2 flask and cultured in a CO2 incubator at 37oC with medium 
replacement every 3 days. Once cells had reached confluence, they were treated with a trypsin-EDTA solution 
(0.3 μM versene and 0.125% trypsin, Invitrogen) to dissociate the cells for sub culture. 
HDF reprogramming was achieved by infecting passage 2-4 HDFs with a commercial non-integrative Sendai 
virus (SeV) Cytotune-iPSC 2.0 kit (Life Technologies), containing three reprogramming plasmid vectors 
(carrying OCT, C-MYC, KLF4 and SOX-2) according to the manufacturer’s instructions. Over the course of 28 
days the HDFs were monitored for morphological changes. Identified colonies were excised and cultured in 
feeder free conditions as described below. 
 
IPSC culture 
IPSCs were routinely cultured on truncated, recombinant vitronectin (VTN-N, Life technologies) coated Costa 6-
well cell culture plastic plates (Corning). The 6-well plates were incubated with 1.0 ml/cm2 VTN-N for 30 
minutes at room temperature or 4oC overnight prior to iPSC seeding. IPSCs were routinely cultured in Essential 
8 (E8, Life Technologies) pluripotent cell culture medium replaced every 24 hours. For sub-culture, iPSC 
colonies were incubated with 0.5 µM EDTA in phosphate buffered saline (PBS) for about 1 minute. The 
colonies were then aspirated and replated into fresh E8 medium supplemented with 10µM Y-27632 (Sigma 
Aldrich) and gently pipetted repeatedly to dissociate the iPSC colonies into smaller cell clusters of around 10-20 
cells. The iPSC clusters were then seeded into new VTN-N coated 6-well plates at a 1:3 ratio. IPSC colonies 
were routinely imaged using Leica DM IL LED inverted microscope (Leica). 
 
Chromosome karyotype analysis and DNA sequencing 
IPSCs were cultured in Costa 6-well plates until confluent. The iPSCs in the plates were sent to the Genomic 
Diagnostics Laboratory, Manchester Centre for Genomic Medicine, Central Manchester University Hospitals 
NHS Foundation Trust, Saint Mary's Hospital, for karyotyping using a standard Giemsa banding protocol. For 
DNA sequencing, genomic DNA from iPSCs were extracted using ISOLATE II Genomic DNA Kit (BIOLINE). 
Sanger DNA sequencing was conducted by the DNA sequencing Service in the University of Manchester using 
intronic primers flanking NOTCH3 exon 4 (PCR primers: sense: 5'-TAGTCGGGGGTGTGGTCAGT-3', 
antisense: 5'-CCTCTGACTCTCCTGAGTAG-3'). Sequencing primer was the same as the sense primer.  
 
Endothelial cell differentiation from iPSCs 
IPSCs were seeded onto a VTN-N coated Costa 6-well plate at around 1 cell cluster (10-20 cells) per cm2 in E8 
medium supplemented with 10 μM Y-27632 and cultured for 24 hours at 37oC. The adherent cells were then 
washed with PBS without calcium and magnesium (Sigma Aldrich), and cultured in fresh E8 media in the 
absence of Y-27632 for 24 hours before changing to Essential 6 (E6, Life technologies) medium supplemented 
with 3 μM CHIR99021 (Calbiochem), 10 ng/ml recombinant BMP4 (Peprotech) and 10 ng/ml recombinant 
FGF2 (Peprotech). After a further 24 hours of culture, the medium was replaced with E6 supplemented with 50 
ng/ml BMP4 and 10 ng/ml FGF2 and renewed every 24 hours until day 6 of differentiation. At day 7 of 
differentiation, BMP was reduced to 25 ng/ml, and 25 ng/ml VEGF-165 (Peprotech) included in the medium. 
The cells were cultured for a further 24 hours before VEGF-165 was increased to 50 ng/ml and BMP4 
withdrawn. The medium was replaced every 24 hours until day 12 of differentiation. 
 
Fluorescence associated cell sorting (FACS)  
At day 12 of iPSC-endothelial differentiation, the differentiated cell population was disassociated by incubation 
with TrypLE (Life Technologies) for 3.5 minutes, and then suspended into 10 ml PBS and washed 3 times by 
centrifugation at 200xg. The cells were then incubated with 5% fetal calf serum (FCS) in PBS containing a PE-
Conjugated Antibody to human VE-Cadherin (clone #123413, cat no: FAB9381P, R&D systems) for 1 hour. 
The cells were washed 3 times with PBS and sorted by FACS to obtain VE-Cadherin+ EC cell population using 
the FACSAria fusion (BD Biosciences) running Diva 8.0.1 software (BD Biosciences). Forward scatter and side 
scatter gating was used to distinguish live from dead cells using a 488 nm laser.  
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Mural cell (MC) differentiation from iPSCs 
IPSCs were passaged onto VTN-N coated Costar 6-well plates at around 1-2 clusters/cm2 in E8 medium 
supplemented with 10 uM of Y-27632 and cultured for 24 hours. The iPSCs were then washed with PBS and 
cultured in E6 medium with 10 μM SB-431542 (Sigma Aldrich) and 10 ng/ml FGF2 for 24 hours. The medium 
was replaced every 24 hours until day 5 of differentiation when the cells were subcultured into new VTN-N 
coated Costar 6-well plates at a density of 0.5x104 cells/cm2. At day 6, the supplements were replaced with 2 
ng/ml TGF-β (Peprotech) and 5 ng/ml PDGF-BB (Peprotech), and medium replaced every 24 hours until day 18 
of differentiation. The iPSC-derived MCs (iPSC-MCs) were characterised by immunofluorescence staining, as 
described below, for alpha-smooth muscle actin (α-SMA), transgelin (TNN1), calponin (CNN1), smoothelin 
(SMTN), smooth muscle myosin heavy chain 11 (SMMHC), Neuroglial antigen 2 (NG2) and platelet derived 
growth factor receptor beta (PDGFRβ). 
 
Primary Cell culture  
Primary human coronary arterial endothelial cells (HCAECs) used as controls for the nitric oxide measurement, 
and primary human coronary artery smooth muscle cells (HCASMCs) used as controls for the in vitro 
angiogenesis, were supplied by Promocell. HCAECs were cultured in Endothelial Cell Growth Medium 2 
(Promocell). HCASMCs were cultured in Smooth Muscle Cell Growth Medium 2 (Promocell) or in Medium 231 
supplemented with Smooth Muscle Growth Supplement (SMGS, Invitrogen) and used between passages 3 and 8. 
For the in vitro angiogenesis and apoptosis confirmatory experiments on primary cultured VSMCs from 
CADASIL patients and healthy controls, ethics approval for recruiting CADASIL and health control individuals 
and isolation of primary SMCs from these individuals was obtained from the West of Scotland Research Ethics 
Service (WS/12/0294) and from the Ethics Board of the Ottawa Hospital Research Institute, Canada 
(#997392132), Canada. Written informed consent was obtained for all study participants in accordance with the 
Declaration of Helsinki. Patients with CADASIL were recruited from the Neurovascular Genetics clinic, Queen 
Elizabeth University Hospital, Glasgow, and healthy controls were volunteers at the OHRI. Subjects  underwent 
a gluteal biopsy under local anaesthetic. Small arteries (<200 µm diameter) were dissected from subcutaneous 
fat. Vessels were cleaned of adventitial tissue and placed in Ham’s F-12  culture medium containing 1% 
gentamicin, collagenase (type 1), elastase, soybean trypsin inhibitor, and BSA and incubated for 1 hour at 37°C 
under constant agitation. The digested tissue was further dissociated by repeated aspiration through a syringe 
with 20G needle. The cell suspension was centrifuged (2000 rpm, 4 minutes) and the cell pellet was resuspended 
in Ham’s F-12 culture medium containing 10% FBS. Cells were seeded onto 25mm round glass coverslips. For 
the first 48 hours, cells were incubated in Ham’s F-12 culture medium containing 10% heat-inactivated FCS. 
Thereafter, VSMCs were maintained in 231 media containing smooth muscle growth supplement (Thermo 
Fisher, Glasgow, UK) with penicillin/streptomycin. Cells from 4 CADASIL patients (mutations Arg169Cys; 
Arg141Cys; Arg54Cys) and 4 controls were used between passages 2 and 6.  
 
Reverse transcription quantitative polymerase chain reaction (RT-qPCR) 
RNA was extracted from cells using the RNeasy mini kit (Qiagen) according to manufacturer’s instruction. 
Lysate was purified by centrifugation through Qiashredder (Qiagen) columns, and samples were treated with 
RNase-Free DNase kits (Qiagen). Two hundred ng/μl of total RNA was reverse transcribed to cDNA using Tetro 
cDNA synthesis kit (Bioline). Ten ng/ml of cDNA and 0.25 µM of forward and reverse primers were used for 
each qPCR reaction. SYBR green reagent (Applied Biosystems; Thermo Scientific) was used for the qPCR 
reaction. QPCR was carried out in a StepOnePlus real-time PCR system (Applied Biosystems) with reaction 
conditions as follows: 94oC for 15 seconds followed by 40 cycles of 95oC for 5 seconds and 60oC for 30 seconds. 
All qPCR reactions were carried out in triplicate. Expression of specific genes was normalised against the 
internal control gene, β-actin. The results were presented either as fold changes compared to a control sample 
using 2-ΔΔCT or ΔCT against internal control. The sequences of the primers used in qRT-PCR are presented in 
Suppl Table 1. The absence of the Cytotune 2.0 Sendai Reprogamming vectors in patient derived iPSCs was 
confirmed by RT-PCR using the manufacturer suggested primers. 
 
Immunofluorescence staining 
Cells were first fixed with 2-4% paraformaldehyde (PFA) in PBS at room temperature for 10-15 minutes and 
washed three times with PBS. Non-specific binding sites were blocked with 5% FCS in PBS for 1 hour at room 
temperature followed by incubation with primary antibody for 1 hour in 5% FCS in PBS. After a further wash 
with PBS, the cells were incubated with secondary antibody in 5% FCS in PBS for 45 minutes and then 
counterstained with a 10 µg/ml DAPI solution. Samples were imaged immediately using a Leica DM IL LED 
inverted microscope. 
 
Western blotting 
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Ten µg protein of cell lysate was loaded to 4-20% mini-protean TGX pre-cast gels (Biorad) and electrophoresed 
in mini-PROTEAN tetra vertical electrophoresis cells (Biorad) at 200V for about 1 hour before transfer to a 
nitrocellulose membrane using a Trans-Blot Turbo transfer system (Biorad). The membrane was then blocked in 
5% Marvel milk in Tris-buffered saline (TBS), and incubated with primary antibody (table 2) in 5% Marvel in 
TBS supplemented with 0.1% Tween-20 (Biorad) (TBS-T) over night at 4°C. The blot was washed three times 
with TBS-T and incubated with HRP conjugated secondary antibody (Dako) at room temperature for 45 minutes. 
After a further wash with TBS-T, the protein bands were visualised using Amersham ECL Start western blotting 
detection reagent and Hyperfilm ECL (GE Healthcare).  
 
In vitro angiogenesis assay 
For the in vitro angiogenesis assay using iPSC-derived vascular cells, 70 μl of 10 mg/ml Matrigel (Corning) 
solution was added into each well of Costar 96-well cell culture plates and incubated for 1 hour at room 
temperature. Ten thousand  iPSC derived ECs (iPSC-ECs) were plated into each well of the Matrigel coated 
plates in E6 medium supplemented with 5 ng/ml VEGF-165 and 2 ng/ml FGF2, and cultured in a CO2 incubator 
at 37°C for 3, 6, 12, 24, 48 and 72 hours, respectively, for capillary network formation. For co-culture of iPSC-
ECs/MCs used in in vitro angiogenesis assays, a mixture of 1x104 iPSC-ECs and 0.5x104 iPSC-MCs were 
seeded into each well of a Matrigel coated 96-well plate and then the same procedure followed for the iPSC-EC 
angiogenesis assay as described above. For determination of roles of VEGF and PDGF in angiogenesis, 
recombinant VEGF-165 (Peprotech), VEGFR2 inhibitor ZM 323881 hydrochloride (R&D Systems, 3 μM), or 
PDGFRβ inhibitor DMPQ dihydrochloride (Santa Cruz Biotechnology, 3 μM) were added to the angiogenesis 
assay, respectively, during cell seeding and replaced with the culture media every 24 hours. To quantify the 
angiogenesis assay, 5 phase contrast images taken from each experimental condition were analysed to measure 
the total network length formed by iPSC-ECs or iPSC-ECs/MCs using the ImageJ software [Fiji ImageJ 
(http://imagej.net/Fiji/Downloads)] with ‘angiogenesis analyser’ plugin. Cultures were imaged at 6, 12, 24, 48 
and 72 hours using a Leica DM IL LED inverted microscope and a Leica DFC365 FX CCD microscope camera 
attachment. Results were presented as total network length. 
For in vitro angiogenesis assay using primary CADASIL VSMCs, the cells were cultured in Medium 231 with 
Smooth Muscle Growth Supplement (Thermo Fisher Scientific). Glass cover slips (13 mm) were coated with 
Geltrex (Thermo Fisher Scientific). Either 1x104 HCASMCs (control) or CADASIL VSMCs in 400 µl were 
added to wells containing the Geltrex-coated cover slips followed by the addition of 2x104 human umbilical vein 
endothelial cells (HUVECs, Promocell). Both cell types were suspended in Endothelial Cell Growth Medium 2 
(Promocell). Cells were then fixed at 3, 6, 24, 48 and 72 hours using 4% paraformaldehyde in PBS for 10 min 
followed by quenching and permeabilization using 0.2 M glycine 0.5% Triton x-100 for 5 minutes. Cell 
networks were stained with anti-human VE-Cadherin antibody (D87F2, Cell Signalling Technology) and anti-
human α-SMA antibody (1A4, DAKO), followed by secondary antibodies Donkey anti-Mouse IgG (H+L) Alexa 
Fluor 555, (A31570, Thermo Fisher Scientific) and Donkey anti-Rabbit IgG (H+L) Alexa Fluor 488 (A21206, 
Thermo Fisher Scientific). Coverslips were mounted with ProLong Gold Antifade Mountant with DAPI (Thermo 
Fisher Scientific).  Images were collected on an Olympus BX51 upright microscope using 4x objectives and 
captured using a Coolsnap ES camera (Photometrics) through MetaVue Software (Molecular Devices). Images 
were processed and analysed using,ImageJ and presented as the total network length. 
For determination of the role of soluble factors secreted from the iPSC-MCs on EC angiogenic network 
formation, either a transwell set-up or use of conditioned medium from iPSC-MCs was employed. For the 
transwell experiment, polyester (PET) membrane transwell-clear insert plates (Corning) were coated with 150 µl 
of 10 mg/ml Matrigel for 1 hour at room temperature. IPSC-ECs were seeded at 1x104 cells per cm2 onto the 
Matrigel coated plates in 2 ml per well of Opti-MEM I media. The iPSC-ECs were allowed to adhere to the 
Matrigel coated surface for 2 hours. In the meantime, iPSC-MCs were seeded onto a 2 cm diameter, 0.4 μm pore 
size PET membrane transwell insert in 1 ml of Opti-MEM I medium and cultured for 3 hours to allow cells to 
adhere. The iPSC-MC-loaded transwell insert was then placed into the iPSC-EC culture well and cultured for up 
to 72 hours for capillary network formation. For the angiogenesis assay using conditioned medium, iPSC-ECs 
were directly placed in the conditioned medium from iPSC-MCs cultures as described above, and seeded into the 
Matrigel coated 96-well plate.  
 
In vivo angiogenesis assay 
All animal experiments were performed according to protocols approved by the Institutional Committee for Use 
and Care of Laboratory Animals at Kings College of London. Differentiated iPSC-MCs and iPSC-ECs from two 
CADASIL and two control individuals (1x106 cells per sample) were mixed with 100 µl of Matrigel and injected 
subcutaneously into the back or flank of NOD.CB17-Prkdcscid/NcrCrl mice. Six injections were conducted for 
each group.  Fourteen days later, the mice were killed and the plugs were harvested, frozen in liquid nitrogen, 
and cryosectioned. Cryosectioned slides were fixed with 4% paraformaldehyde in PBS at 4°C, and then stained 
with anti-human mitochondria (EMD Millipore) and anti-human calponin antibody (Abcam) as described in the 
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immunofluorescence staining section above.  
 
Conditioned media collection from iPSC-MC cultures 
IPSC-MCs were seeded at 1x104 cells/cm2 onto tissue culture plastic plates in Opti-MEM I Reduced Serum 
Medium (Gibco, Life Technologies) and cultured for 24 hours. The medium was replaced with fresh Opti-MEM 
medium and the cells were cultured for a further 48 hours. The medium was then harvested and centrifuged at 
500xg for 5 mins to be used either immediately or aliquotted and stored at -80oC.  
 
Angiogenesis proteome profiler array analysis 
The Proteome Profiler Human Angiogenesis Array Kit (ARY007, R&D systems) was used to assess differences 
in angiogenesis related proteins secreted from the control and CADASIL iPSC-MCs in the conditioned media 
collected from iPSC-MC cultures as described above according to the manufacturer’s protocol. The kit consists 
of 4 nitrocellulose membranes which contain 55 capture antibodies absorbed onto each membrane, in duplicate. 
The blots were quantified by densitometry using the ImageJ software. 
 
ELISA analysis 
Conditioned medium collected from cultures of iPSC-MCs, primary VSMCs from CADASIL patient, or 
hCASMCs were subject to ELISA assays using Human VEGF Quantikine ELISA kit (R&D Systems) to 
quantify the concentrations of VEGF. The assay was conducted according to the manufacturer’s instruction. 
 
Apoptosis assay  
One thousand iPSC-MCs or primary microvascular SMCs from CADASIL patients, or 1.5x103 iPSC-ECs per 
well were seeded into white opaque 96-Well Microplates (Pierce, Thermo Scientific), respectively, and cultured 
for 3 hours to allow cells to adhere. The cells were then washed with PBS and the medium replaced with 50 µl 
Opti-MEM containing different concentrations of hydrogen peroxide (1 – 1000 μm) or Staurosporine (0.1 – 100 
nM), respectively, and incubated for 24 hours. The Caspase3/7 activity was then measured using the Caspase-
Glo 3/7 Assay kit (Promega). Briefly, an equal volume of the Caspase-Glo 3/7 substrate was added to each well 
of the cell culture plate and mixed well using a microplate vortex mixer. The plate was then incubated at room 
temperature for one hour before reading luminescence using GloMax-multi+ microplate multimode reader 
(Promega). 
For measuring the impact of CADASIL iPSC-MCs on the survival of iPSC-ECs, iPSC-MCs and iPSC-ECs were 
mixed to a 1:1 ratio and seeded into single wells of a Costar 6-well plate at a density of 1x104 cells/cm2 and co-
cultured for 48 hours. The co-cultured iPSC-EC and iPSC-MCs were dissociated in TrypLE for 3 minutes, 
centrifuged at 200xg for 5 mins and washed with PBS. The cell pellets were suspended in 5% FCS in E6 
medium containing anti-CD31 Dynabeads (Thermo Fisher Scientific) and incubated for 30 mins at room 
temperature. The iPSC-ECs and iPSC-MCs were then separated by magnetic associated cell sorting (MACS). 
Post sorted iPSC-ECs and iPSC-MCs were subject to the caspase3/7 assays as mentioned above.  
 
Nitric oxide measurement using Griess reaction 
Nitric oxide concentration was quantified using the Griess Reagent System (Promega). Fresh conditioned media 
were collected from cultured ECs and centrifuged at 500xg for 5 minutes to remove cell debris. The supplied 
sulphanilamide solution and N-1-napthylethylenediamine dihydrochloride (NED) solutions were allowed to 
equilibrate at room temperature for 30 minutes. Fifty μl of the conditioned media or a nitrile standard were added 
to each well of a 96-well microplate (ThermoFisher Scientific, Nunc). Fifty ul of sulphanilamide solution was 
added to each well and incubated at room temperature for 10 minutes, 50 ul of NED solution was then added to 
each well and incubated at room temperature, protected from light, for a further 10 minutes. The absorbance of 
each well was measured immediately at 530nm using GloMax-multi+ microplate multimode plate reader 
(Promega). Samples were quantified according to a standard curve of nitrile concentration plotted against 
absorbance.  
 
Small interfering RNA (siRNA) NOTCH3 knockdown in iPSC-MCs 
NOTCH3 specific siRNA sequences and a scrambled negative control siRNA were purchased from Qiagen 
(Venlo, Netherlands): ‘FlexiTube GeneSolution GS4854’ and ‘Negative Control’, respectively. NOTCH3 siRNA 
SI00009513 (Seq 5’ AAG GAA TAG TTA ACA CTC AAA 3’) or scrambled siRNA (5’ AAT TCT CCG AAC 
GTG TCA CGT 3’) were delivered into 2x106 iPSC-MCs by the 4D-nucleofector system (AAF-1002B) + X unit 
(AAF-1002X) (Lonza) using the 4D p3 kit (Lonza) with programme CM138. After nucleofection, 2ml of pre-
warmed Promocell Smooth Muscle Cell Growth Medium 2 (Promocell) was immediately added into the cell 
suspension, and the cells were reseeded into Costar 6-well plates (Corning) and cultured for 24 hours before total 
RNA extraction for qRT-PCR, cell lysis preparation for western blotting or reseeding into Matrigel coated Costa 
96-well plates for in vitro angiogenesis analysis.  
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Statistics 
Gaussian distribution of each data set was determined by the Shapiro-Wilks test using Microsoft excel utilising 
the Real statistics addon available from http://www.real-statistics.com/free-download. Data that displayed a P 
value greater than 0.05 was considered to be normally distributed and further statistical tests were then applied. 
Data were presented as mean ± SEM. Unpaired Student t-test was used to compare differences between results 
from two groups of samples. Where more than two means were compared, one-way or two-way ANOVA was 
performed in Microsoft excel using the data analysis tool and ‘ANOVA, single factor’. Tukey’s post-hoc test or 
Bonferroni post-hoc test were then followed to confirm the differences between two groups. A p-value ≤ 0.05 
was considered as statistically significant.  
 
 
